PegBio (HKG:2565) received the first royalty payment of HK$61 million from Shanghai Tenry Pharmaceutical over a licensing deal covering visepegenatide in China, according to a Friday filing with the Hong Kong bourse.
The medicine, sold under the Paidakang brand name, is intended to treat type 2 diabetes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments